Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (Nasdaq: COCP) entered into a $5 million private placement with longtime investor OPKO Health (Nasdaq: OPK). Cocrystal sold 5,474,053 common shares to OPKO at $0.9134 per share, equal to the Nasdaq Consolidated Bid Price on the closing day, with no warrants or other derivatives issued.
According to Cocrystal, the proceeds support advancement of its lead norovirus candidate CDI-988, with topline Phase 1b data expected by the end of the fourth quarter of 2026. Both companies highlighted OPKO’s longstanding support and confidence in Cocrystal’s antiviral pipeline.
Cocrystal Pharma (Nasdaq: COCP) appointed James Sapirstein as Chief Executive Officer, effective immediately, and plans to add him to the Board. The company is a clinical-stage biotech focused on novel antiviral therapeutics.
Sam Lee and Jim Martin step down as Co-CEOs; Lee becomes President and future Chief Scientific Officer, while Martin remains Chief Financial Officer. Sapirstein brings extensive antiviral development experience, participation in or leadership of 23 product launches, and a background as CEO or senior executive at several biopharma companies.
Cocrystal Pharma (Nasdaq: COCP) reported discovery-stage pan-viral replication inhibitors targeting hantavirus, bunyavirus and influenza. These direct-acting antivirals target a conserved region of the viral L-protein replication enzyme. In vitro data show potency with IC50 <50 nM against hantaan virus, related to Andes hantavirus. The company also highlighted its pan-viral protease inhibitor CDI-988, now in a Phase 1b norovirus challenge study, and plans to advance a pan-viral lead molecule to address viral diseases that currently lack approved antivirals or vaccines.
Cocrystal Pharma (Nasdaq: COCP) reported first quarter 2026 revenue of $225,000, all from an NIH SBIR award, versus no revenue in 2025. Net loss was $2.3 million ($0.17/share), similar to 2025. Unrestricted cash was $4.7 million with working capital of $3.7 million.
The company advanced CDI-988 for norovirus, completing enrollment in the first Phase 1b human challenge cohort and enrolling prevention/treatment cohorts, and obtained FDA Fast Track. It also progressed its influenza programs, including CC-42344 and an influenza A/B polymerase initiative supported by NIH funding.
Cocrystal Pharma (Nasdaq: COCP) presented klinical and preclinical data for CDI-988, a first oral direct-acting 3CL protease inhibitor for norovirus, at ICAR 2026. Key disclosures: Phase 1 safety data, ongoing Phase 1b human challenge study with stage 1 fully enrolled, and FDA Fast Track designation.
Phase 1 found CDI-988 generally safe to 1,200 mg; Phase 1b uses 1,200 mg twice daily for five days to assess prevention and treatment endpoints including symptom incidence and viral shedding.
Cocrystal Pharma (Nasdaq: COCP) announced that the U.S. FDA granted Fast Track designation to CDI-988, an oral direct-acting protease inhibitor being developed to prevent and treat norovirus infection. The designation enables earlier FDA interactions, rolling NDA review, and potential Priority Review.
CDI-988 targets a conserved 3CL protease region; a Phase 1b norovirus challenge study is currently underway at Emory University to evaluate both prevention and treatment.
Cocrystal Pharma (Nasdaq: COCP) reported 2025 results and pipeline updates on March 31, 2026. The company began a Phase 1b norovirus human challenge study at Emory for oral protease inhibitor CDI-988.
Key 2025 financials: R&D $5.1M (vs $12.5M), G&A $4.0M (vs $5.3M), net loss $8.8M ($0.78/share, vs $17.5M), cash $7.7M (vs $9.9M), working capital $5.9M, and 11.3M shares outstanding.
Cocrystal Pharma (Nasdaq: COCP) announced first subjects dosed in a Phase 1b randomized, double-blind, placebo-controlled human challenge study evaluating oral antiviral CDI-988 for prevention and treatment of norovirus. The study at Emory will enroll up to 40 healthy adults aged 18–49 infected with GII.2 (Snow Mountain Virus).
Primary endpoint: reduction in clinical symptom incidence versus placebo. Secondary endpoints: viral shedding, disease severity, safety, and pharmacokinetics. CDI-988 previously showed favorable Phase 1 safety; FDA issued a Study May Proceed letter in Sept 2025 and Emory IRB approved the study in Dec 2025. No approved norovirus treatments exist; norovirus causes an estimated $60 billion annual global economic burden.
Cocrystal Pharma (Nasdaq: COCP) will present initial Phase 1 and ongoing Phase 1b norovirus challenge study data for CDI-988 at ICAR2026, April 27–May 1 in Prague.
CDI-988 is described as the company’s first oral, direct-acting protease inhibitor developed for prevention and treatment of acute norovirus gastroenteritis and as a pan-viral 3CL protease inhibitor.
Cocrystal Pharma (Nasdaq: COCP) received Institutional Review Board approval from Emory University School of Medicine to start a Phase 1b human challenge study of CDI-988 for prevention and treatment of norovirus.
Key facts: the study follows FDA IND clearance and a Study May Proceed letter, will enroll up to 40 healthy adults (ages 18-49), use norovirus GII.2 challenge, and expects subject enrollment in Q1 2026. Primary endpoint is reduction in clinical symptoms; secondary endpoints include viral shedding and disease severity.